Biospective has leading expertise in models to evaluate the efficacy of novel therapeutic agents. We are a one-stop shop providing a full range of preclinical services, including in-house or sponsor model generation, housing, dosing, imaging, behavioral testing, and histology/IHC studies.
Biospective’s in vivo Tau transgenic mice and Tau fibril spreading models demonstrate a rapidly progressive and robust propagation of tau pathology. These models rely on the inoculation of synthetic tau fibrils to initiate Alzheimer’s disease-like intracellular neurofibrillary tangles and transmit the pathology to anatomically-connected brain regions. Common injection sites include the hippocampus, the cerebral cortex, and the anterior olfactory nucleus (AON).
Biospective’s scientists work closely with sponsors to determine the most appropriate Cuprizone and EAE models, as well as biomarkers, to assess therapies targeting demyelination and remyelination, inflammation, and neuroprotection.
Biospective’s in vivo PD models rely on the inoculation of synthetic α-synuclein fibrils to initiate Parkinson’s disease-like Lewy bodies/Lewy neurites and transmit the pathology to anatomically-connected regions. These transgenic mice and α-synuclein fibril spreading models can mimic early “prodromal stage” or late “motor stage” of PD. Common injection sites include the striatum, the cerebral cortex, the substantia nigra, and the anterior olfactory nucleus (AON).